BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37607790)

  • 1. Clinical characteristics in patients with non-alcoholic steatohepatitis in Japan: a case-control study using a 5-year large-scale claims database.
    Tokutsu K; Ito K; Kawazoe S; Minami S; Fujimoto K; Muramatsu K; Matsuda S
    BMJ Open; 2023 Aug; 13(8):e074851. PubMed ID: 37607790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
    J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
    Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
    Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
    Aminian A; Al-Kurd A; Wilson R; Bena J; Fayazzadeh H; Singh T; Albaugh VL; Shariff FU; Rodriguez NA; Jin J; Brethauer SA; Dasarathy S; Alkhouri N; Schauer PR; McCullough AJ; Nissen SE
    JAMA; 2021 Nov; 326(20):2031-2042. PubMed ID: 34762106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
    García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
    Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
    Shelley K; Articolo A; Luthra R; Charlton M
    BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
    Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
    JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
    Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
    Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study.
    Hamid O; Eltelbany A; Mohammed A; Alsabbagh Alchirazi K; Trakroo S; Asaad I
    Ann Hepatol; 2022; 27(5):100727. PubMed ID: 35700934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
    Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
    Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    Ferrusquía-Acosta J; Bassegoda O; Turco L; Reverter E; Pellone M; Bianchini M; Pérez-Campuzano V; Ripoll E; García-Criado Á; Graupera I; García-Pagán JC; Schepis F; Senzolo M; Hernández-Gea V
    J Hepatol; 2021 Apr; 74(4):811-818. PubMed ID: 33068638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
    Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
    J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.
    Haldar D; Kern B; Hodson J; Armstrong MJ; Adam R; Berlakovich G; Fritz J; Feurstein B; Popp W; Karam V; Muiesan P; O'Grady J; Jamieson N; Wigmore SJ; Pirenne J; Malek-Hosseini SA; Hidalgo E; Tokat Y; Paul A; Pratschke J; Bartels M; Trunecka P; Settmacher U; Pinzani M; Duvoux C; Newsome PN; Schneeberger S;
    J Hepatol; 2019 Aug; 71(2):313-322. PubMed ID: 31071367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation.
    Tokodai K; Karadagi A; Kjaernet F; Romano A; Ericzon BG; Nowak G
    Scand J Gastroenterol; 2019 Feb; 54(2):233-239. PubMed ID: 30999770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.
    Lembo E; Russo MF; Verrastro O; Anello D; Angelini G; Iaconelli A; Guidone C; Stefanizzi G; Ciccoritti L; Greco F; Sessa L; Riccardi L; Pompili M; Raffaelli M; Vecchio FM; Bornstein SR; Mingrone G; Gastaldelli A; Capristo E
    Diabetes Metab; 2022 Sep; 48(5):101363. PubMed ID: 35760372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.
    Yatsuji S; Hashimoto E; Tobari M; Taniai M; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2009 Feb; 24(2):248-54. PubMed ID: 19032450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.